Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2025-07-01 Epub Date: 2025-07-27 DOI:10.1080/14728222.2025.2537414

Tatyana Storozhenko, Olga Petyunina, Alexander Berezin, Mykola Kopytsya

{"title":"Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?","authors":"Tatyana Storozhenko, Olga Petyunina, Alexander Berezin, Mykola Kopytsya","doi":"10.1080/14728222.2025.2537414","DOIUrl":null,"url":null,"abstract":"Introduction: Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in immune regulation, inflammation, and tissue homeostasis. Elevated MIF levels contribute to the progression of various cardiovascular diseases (CVDs), making it an attractive therapeutic target. However, the pleiotropic nature and complexity of MIF context-dependent effects pose significant challenges for clinical translation, but also offer unique opportunities to develop new precision medicine-based tools.Areas covered: This review summarizes the biological functions of MIF and its homolog MIF-2 in CVD pathogenesis, along with the current landscape of therapies targeting MIF. We highlight recent preclinical findings, discuss ongoing controversies surrounding MIF's dual roles, and explore the potential of personalized approaches.Expert opinion: MIF represents a promising yet complex target in cardiovascular medicine. Future success in clinical application will depend on the development of highly selective modulators, integration of patient stratification strategies and MIF-based interventions as part of multimodal cardiovascular care.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"29 7","pages":"415-421"},"PeriodicalIF":4.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2025.2537414","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in immune regulation, inflammation, and tissue homeostasis. Elevated MIF levels contribute to the progression of various cardiovascular diseases (CVDs), making it an attractive therapeutic target. However, the pleiotropic nature and complexity of MIF context-dependent effects pose significant challenges for clinical translation, but also offer unique opportunities to develop new precision medicine-based tools.

Areas covered: This review summarizes the biological functions of MIF and its homolog MIF-2 in CVD pathogenesis, along with the current landscape of therapies targeting MIF. We highlight recent preclinical findings, discuss ongoing controversies surrounding MIF's dual roles, and explore the potential of personalized approaches.

Expert opinion: MIF represents a promising yet complex target in cardiovascular medicine. Future success in clinical application will depend on the development of highly selective modulators, integration of patient stratification strategies and MIF-based interventions as part of multimodal cardiovascular care.

查看原文本刊更多论文

巨噬细胞迁移抑制因子（MIF）：能否为心血管疾病的未来治疗铺平道路？

巨噬细胞迁移抑制因子（Macrophage migration inhibitory factor， MIF）是一种参与免疫调节、炎症和组织稳态的多功能细胞因子。MIF水平升高有助于各种心血管疾病（cvd）的进展，使其成为一个有吸引力的治疗靶点。然而，MIF环境依赖效应的多效性和复杂性为临床翻译带来了重大挑战，但也为开发新的精准医学工具提供了独特的机会。涵盖领域：本文综述了MIF及其同源物MIF-2在心血管疾病发病机制中的生物学功能，以及目前针对MIF的治疗前景。我们强调了最近的临床前研究结果，讨论了围绕MIF双重角色的持续争议，并探索了个性化方法的潜力。专家意见：MIF代表了心血管医学中一个有前景但复杂的靶点。未来临床应用的成功将取决于高选择性调节剂的发展，患者分层策略的整合以及作为多模式心血管护理一部分的基于mif的干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.